4th International Conference on Innovations and Advances in Cancer Research and Treatment
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 4th International Conference on Innovations and Advances in Cancer Research and Treatment — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
4th International Conference on Innovations and Advances in Cancer Research and Treatment
The 4th International Conference on Innovations and Advances in Cancer Research and Treatment brings together leading oncologists, researchers, clinicians, healthcare professionals, and industry experts to explore cutting-edge advancements in cancer diagnosis, therapy, and patient care. This multidisciplinary event fosters collaboration across academia, healthcare systems, and biotechnology sectors to accelerate the translation of scientific discoveries into clinical practice.
About the Conference
This conference serves as a global platform to discuss emerging trends, challenges, and breakthroughs in oncology. Topics will include precision medicine, immunotherapy, targeted therapies, liquid biopsies, AI-driven diagnostics, and survivorship care. Attendees will engage in interactive sessions, poster presentations, and networking opportunities to drive innovation in cancer treatment and improve patient outcomes worldwide.
Key Focus Areas
- Genomics and personalized cancer therapies
- Advancements in immunotherapy and checkpoint inhibitors
- AI and machine learning in cancer detection and prognosis
- Minimally invasive surgical techniques and robotics
- Psychosocial support and quality-of-life interventions
- Global disparities in cancer care and access to treatment
- Regulatory frameworks for novel oncology drugs and devices
Who Should Attend
- Oncologists and hematologic oncologists
- Cancer researchers and lab scientists
- Medical oncology nurses and care coordinators
- Pharmaceutical and biotech industry representatives
- Health policy makers and public health officials
- Academic institutions and clinical trial coordinators
- Patient advocacy groups and nonprofit organizations
Event Highlights
Keynote Addresses: Renowned experts will deliver insights on the future of oncology. Workshops: Hands-on training in genomic sequencing and clinical trial design. Exhibition: Showcase of innovative medical devices, diagnostic tools, and digital health solutions. Networking: Dedicated sessions to connect with global peers and potential collaborators.
Call for Participation
Researchers and clinicians are invited to submit abstracts for oral or poster presentations. Early bird registration is open until [insert date]. For sponsorship or exhibition inquiries, contact [insert contact details].
Join us in shaping the future of cancer care through innovation, education, and global collaboration.
Data sheet
4th International Conference on Innovations and Advances in Cancer Research and Treatment – Event Attendee & Buyer Profile Analysis
Event date: 8 October 2026 - 9 October 2026
Location: Tokyo, Japan
Event status: Upcoming
Research date: 30 June 2026
Event Overview
| Event Name | 4th International Conference on Innovations and Advances in Cancer Research and Treatment |
| Event Date | 8 October 2026 - 9 October 2026 |
| Event Status | Upcoming |
| Venue | ANA Crowne Plaza Narita listed in provided details; venue should be re-verified against the official event page because the supplied note also mentions possible various locations within Tokyo. |
| City | Tokyo |
| State / Region | Tokyo Prefecture / Greater Tokyo region |
| Country | Japan |
| Organizer | Organizer not confirmed in the supplied materials. |
| Official Event Website | Official website not supplied for verification in the provided materials. |
| Event Type | International medical and scientific conference |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology |
| Audience Reach | International scientific conference with likely national and cross-border medical participation based on event title and subject matter. Current-year geographic breakdown not confirmed. |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low at present. No official attendee, exhibitor, or footfall figures were supplied. |
| Main Purpose of Event | To convene oncologists, researchers, clinicians, healthcare stakeholders, and industry participants around innovations in cancer diagnosis, treatment, translational research, and patient care. |
About the Event
The 4th International Conference on Innovations and Advances in Cancer Research and Treatment is positioned as a multidisciplinary oncology conference focused on scientific, clinical, and translational progress in cancer care. Based on the supplied description, the program is expected to cover precision medicine, immunotherapy, targeted therapies, liquid biopsy applications, AI-driven diagnostics, survivorship, psychosocial support, and global access challenges.
For business development and attendee profiling, this is most relevant as a high-value knowledge and partnership event rather than a large-scale public expo. The strongest attendee groups are likely to include clinical decision-makers, principal investigators, hospital oncology leaders, academic researchers, biotech and pharma R&D teams, diagnostics companies, device innovators, regulatory specialists, and health-system collaborators. It is especially useful for outreach tied to research partnerships, clinical technologies, diagnostic platforms, trial support services, medical devices, and oncology-focused B2B solutions.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Hospital oncology leaders | Cancer centers, university hospitals, specialty hospitals | Influence clinical adoption, pilot evaluation, treatment pathway decisions, and referral networks | High relevance for therapeutics, diagnostics, medical devices, and digital oncology tools |
| Academic researchers and principal investigators | Universities, research institutes, translational oncology labs | Shape trial collaborations, biomarker validation, and scientific partnerships | High relevance for lab technologies, data platforms, CRO services, and grant-supported innovations |
| Biopharma R&D and clinical development teams | Pharmaceutical and biotechnology companies | Evaluate partnerships, pipeline opportunities, translational science, and trial assets | High relevance for drug development support, biomarkers, trial recruitment, and manufacturing partners |
| Diagnostics and genomics buyers | Clinical labs, molecular diagnostics firms, pathology groups | Assess platforms for sequencing, liquid biopsy, pathology, and precision diagnostics | High relevance for assay developers, instrumentation, software, and AI pathology vendors |
| Medical device and surgical innovation teams | Robotics firms, imaging companies, device manufacturers, hospital technology teams | Influence capital equipment assessment and innovation partnerships | Relevant for imaging, robotic surgery, minimally invasive tools, and interoperability vendors |
| AI and health IT leaders | Healthcare IT firms, hospitals, digital health companies, software providers | Drive evaluation of analytics, clinical AI, workflow software, and decision support systems | High relevance for oncology informatics, medical imaging AI, and secure data-sharing solutions |
| Clinical operations and procurement teams | Hospitals, research networks, biopharma firms | Manage sourcing of clinical tools, services, equipment, and external vendors | Important for vendor qualification and medium-term procurement pipelines |
| Regulatory and market access specialists | Pharma, biotech, medtech, consulting firms | Support approval strategy, evidence planning, reimbursement and compliance decisions | Relevant for consultancies, quality systems, evidence generation, and commercialization partners |
| Patient advocacy and nonprofit health leaders | Cancer foundations, support organizations, public health groups | Influence patient engagement, outreach, awareness, and care pathway design | Relevant for education programs, patient services, and survivorship platforms |
| Investors and strategic partners | Healthcare investors, venture teams, strategic innovation groups | Evaluate commercialization potential and partnership pipelines | Relevant for early-stage oncology ventures, platform technologies, and co-development opportunities |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Tokyo | Clinicians, researchers, hospitals, universities, biotech firms, medical associations | Very high | Strong concentration of academic medicine, specialist hospitals, and life sciences activity |
| Greater Tokyo / Kanto region | Regional hospitals, research institutes, pharma and diagnostics operations | High | Likely catchment for nearby attendees and local industry delegates |
| Japan national market | National oncology, academic, biotech, medtech, and public health participants | High | Likely national reach given the international conference format and subject matter |
| Asia-Pacific | Researchers, clinicians, and industry delegates from regional cancer centers and life sciences firms | Medium to high | International branding suggests probable APAC participation, but current-year country list is not confirmed |
| Europe and North America | Selected scientific speakers, pharma, biotech, device, and academic delegates | Medium | Likely international scientific interest area rather than mass attendance without official country data |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The event title, conference theme, and scientific subject matter indicate international relevance, although current-year attendee geography remains unverified. |
| National | Secondary practical reach | Japan-based hospitals, universities, cancer centers, and life sciences companies are likely to form a strong base of participants. |
| Regional | Secondary operational reach | Tokyo and the Kanto region are likely to contribute a significant share of nearby academic and healthcare attendance. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| National Cancer Center Japan | Cancer research and clinical care institution | Direct fit for oncology research, diagnostics, treatment innovation, and academic collaboration | ncc.go.jp | Chief of Oncology, Principal Investigator, Clinical Research Director, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| The University of Tokyo Hospital | Academic medical center | Relevant for translational oncology, AI diagnostics, and precision medicine programs | h.u-tokyo.ac.jp | Oncology Department Head, Professor, Clinical Innovation Director, Hospital Procurement | Strong Market Fit, Attendance Not Confirmed |
| Keio University Hospital | Academic hospital | Likely interest in advanced cancer therapies, surgery, imaging, and clinical research partnerships | hosp.keio.ac.jp | Director Oncology Center, Clinical Trials Director, Professor Oncology, Sourcing Lead | Strong Market Fit, Attendance Not Confirmed |
| The Cancer Institute Hospital of JFCR | Specialist cancer hospital | High relevance for oncology-specific diagnostics, therapeutics, and patient care models | jfcr.or.jp | Medical Director, Department Chair, Research Program Lead, Procurement Officer | Strong Market Fit, Attendance Not Confirmed |
| St. Luke's International Hospital | Hospital and clinical care provider | Relevant for oncology care pathways, diagnostics, and digital health adoption | luke.or.jp | Oncology Service Line Director, Clinical Operations Director, IT Director Healthcare | Strong Market Fit, Attendance Not Confirmed |
| Astellas Pharma | Pharmaceutical company | Relevant for oncology R&D, partnerships, biomarker strategy, and commercialization discussions | astellas.com | VP Oncology, Clinical Development Director, Medical Affairs Director, Alliance Manager | Strong Market Fit, Attendance Not Confirmed |
| Takeda | Pharmaceutical company | Major oncology and translational medicine stakeholder relevant for partnering and innovation sourcing | takeda.com | Head of Oncology, Global Medical Affairs, Clinical Procurement, External Innovation Lead | Strong Market Fit, Attendance Not Confirmed |
| Daiichi Sankyo | Pharmaceutical company | Strong fit for targeted therapies, oncology pipeline engagement, and academic collaboration | daiichisankyo.com | Oncology Franchise Lead, R&D Director, Biomarker Lead, Partnerships Director | Strong Market Fit, Attendance Not Confirmed |
| Chugai Pharmaceutical | Pharmaceutical company | Relevant to immunotherapy, targeted drugs, diagnostics partnerships, and scientific exchange | chugai-pharm.co.jp | Medical Affairs Director, Oncology Research Lead, Alliance Director, Clinical Operations Lead | Strong Market Fit, Attendance Not Confirmed |
| Sysmex Corporation | Diagnostics and medical technology company | Relevant for cancer diagnostics, laboratory systems, and biomarker workflows | sysmex.co.jp | Diagnostics Business Director, Product Manager Oncology, Strategic Partnerships Manager | Strong Market Fit, Attendance Not Confirmed |
| Fujifilm Healthcare | Healthcare imaging and medical technology company | Relevant to imaging, AI-assisted detection, and oncology care technology | fujifilm.com | Healthcare Solutions Director, Imaging Product Lead, Clinical Innovation Manager | Strong Market Fit, Attendance Not Confirmed |
| Olympus Corporation | Medical device manufacturer | Relevant for minimally invasive procedures, oncology imaging, and surgical innovation | olympus-global.com | Medical Affairs Lead, Product Strategy Director, Surgical Innovation Director | Strong Market Fit, Attendance Not Confirmed |
Note: Current-year attendee, exhibitor, sponsor, and speaker organization lists were not supplied. The companies above are included as strong prospecting targets and sector-relevant buyer organizations, not as confirmed attendees.
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Medical Officer / Medical Director Oncology | Clinical Leadership | C-Level / Executive | Influences adoption of treatments, technologies, and strategic partnerships |
| 2 | Director of Oncology / Cancer Center Director | Oncology Services | Director | Key decision-maker for oncology programs, equipment, and clinical initiatives |
| 3 | Principal Investigator / Professor of Oncology | Research | Senior | Shapes research partnerships, trial participation, and scientific adoption |
| 4 | Clinical Research Director | Clinical Research | Director | Important for study support, CRO services, patient recruitment, and trial technologies |
| 5 | Head of Translational Medicine | R&D | VP / Director | Relevant for biomarker platforms, data integration, and drug development partnerships |
| 6 | Medical Affairs Director | Medical Affairs | Director | Engages in KOL relationships, evidence communication, and adoption planning |
| 7 | Director of Pathology / Molecular Diagnostics Lead | Diagnostics / Laboratory | Director | Critical for assay selection, pathology workflows, and genomic testing adoption |
| 8 | CTO / CIO / Health IT Director | Technology | Executive / Director | Relevant for AI diagnostics, interoperability, data platforms, and cyber-secure clinical systems |
| 9 | Procurement Manager / Strategic Sourcing Manager | Procurement | Manager | Manages vendor onboarding, equipment sourcing, and purchasing process execution |
| 10 | Business Development Director / Alliance Manager | Business Development | Director | Key for licensing, collaborations, co-development, and strategic partnerships |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core audience segment for clinical oncology, care delivery, and technology adoption | Cancer centers, hospitals, oncology departments |
| 2 | Pharmaceuticals | Central to targeted therapies, immunotherapy, and pipeline discussions | Oncology drug development and medical affairs outreach |
| 3 | Biotechnology | Relevant for precision medicine, biomarkers, cell therapy, and innovation partnerships | Biomarker platforms and translational research partnerships |
| 4 | Medical Devices | Relevant for oncology equipment, imaging, surgery, and diagnostic hardware | Imaging, pathology, surgical, and therapeutic devices |
| 5 | Research | Academic and translational research institutions are likely attendees | Universities, cancer institutes, translational labs |
| 6 | Higher Education | University hospitals and medical faculties are relevant participants | Professor-led trials and academic partnerships |
| 7 | Information Technology & Services | AI diagnostics, analytics, and clinical workflow software are explicit focus areas | Clinical AI and data platforms for oncology |
| 8 | Computer Software | Relevant for decision support, image analysis, patient data systems, and digital pathology | AI-assisted oncology tools and workflow software |
| 9 | Government Administration | Relevant where public health agencies, cancer programs, or national research bodies participate | Public oncology initiatives and health system programs |
| 10 | Management Consulting | Relevant for market access, regulatory strategy, and healthcare transformation support | Advisory on oncology commercialization and adoption pathways |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Unconfirmed | No official attendance number supplied | No safe estimate should be presented without organizer evidence |
| Exhibitor count | Not publicly confirmed | Unconfirmed | No official exhibitor list supplied | This event appears conference-led rather than trade-floor-led based on provided description |
| Buyer count | Not publicly confirmed | Unconfirmed | No registration breakdown supplied | Audience likely consists of clinical, academic, and industry professionals |
| Speaker count | Not publicly confirmed | Unconfirmed | No agenda or faculty list supplied | Conference description indicates multiple sessions and poster presentations |
| Sponsor count | Not publicly confirmed | Unconfirmed | No sponsorship materials supplied | Could be important if medical device, diagnostics, or pharma partners are involved |
| Historical attendance | Not available in supplied materials | Historical data unavailable | No prior-year official reports supplied | Would improve forecast confidence if prior editions publish attendee totals |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Precision medicine | Better patient stratification and therapy matching | Clinical validation, biomarker collaboration, genomics workflow discussions | Genomics platforms, companion diagnostics, bioinformatics, data integration tools |
| Immunotherapy and targeted therapies | Pipeline innovation, trial design, outcome improvement | Pharma partnering, translational research, investigator engagement | Drug development services, biomarker assays, medical affairs support |
| AI in cancer detection and prognosis | Earlier detection, workflow efficiency, improved prognosis models | Pilot programs, software demos, integration conversations with hospitals and labs | Clinical AI, imaging analytics, pathology software, predictive modeling platforms |
| Liquid biopsy and diagnostics | Less invasive testing and monitoring capabilities | Laboratory partnerships, assay validation, adoption pathway discussions | Sequencing, assay kits, molecular diagnostics instrumentation |
| Minimally invasive surgery and robotics | Improved outcomes, reduced recovery time, procedural precision | Demonstrations, clinical case-sharing, technology evaluation | Surgical devices, robotics, imaging-guided systems, OR technologies |
| Survivorship and psychosocial support | Whole-patient care and quality-of-life improvement | Partnerships with care programs, nonprofits, digital patient services | Patient engagement tools, support services, remote monitoring, education platforms |
| Regulatory frameworks | Approval clarity and evidence requirements | Consulting conversations, compliance planning, cross-border strategy | Regulatory advisory, QMS support, market access strategy, clinical evidence services |
| Global disparities in cancer care | Access, affordability, and scalable care delivery | Public-private collaboration and grant-aligned programs | Affordable diagnostics, telehealth, NGO partnerships, scalable service models |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | Highly relevant for oncology, diagnostics, medtech, healthcare IT, and research-service suppliers |
| Decision-maker availability | Medium to High | Scientific and clinical leaders are likely present, though direct procurement attendees may be fewer than at a trade expo |
| Data collection potential | Medium | Useful for curated account targeting, but limited if no public exhibitor or attendee lists are released |
| Apollo targeting potential | High | The event aligns well with vertical industry targeting by healthcare, pharma, biotech, diagnostics, and research roles |
| Geographic targeting potential | High | Japan, APAC, and international oncology centers can be segmented effectively |
| Best outreach approach | High-value account-based outreach | Use role-based messaging tied to innovation themes, trials, diagnostics, AI, or care delivery outcomes |
| Overall lead quality | High | Strong strategic fit for specialized B2B healthcare offerings, though list-building confidence depends on official participant visibility |
| Best use case | Thought leadership targeting and strategic account mapping | Best for identifying oncology innovation buyers, investigators, and hospital or pharma stakeholders rather than mass transactional lead capture |
| Limitations / risks | Medium | Current-year attendee confirmation, sponsor details, and official counts were not available in the supplied materials |
Suitability for B2B attendee list building: Moderate to high for targeted account mapping and job-title-based prospecting; lower for verified current-year attendee list sales unless the organizer publishes attendee, speaker, sponsor, or partner directories.
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Medical Devices; Research; Higher Education; Information Technology & Services; Computer Software; Government Administration; Management Consulting | Core buyer universe aligned to oncology innovation and care delivery |
| Departments | Research, Medical, Clinical Operations, Procurement, Information Technology, Business Development, Innovation, Laboratory, Pathology | Targets both scientific and commercial buying influence |
| Seniority | C-Level, VP, Director, Head, Manager, Partner, Professor | Captures both executive and practical adoption stakeholders |
| Job titles | Medical Director Oncology, Cancer Center Director, Principal Investigator, Professor Oncology, Clinical Research Director, Medical Affairs Director, Head of Translational Medicine, Director of Pathology, Molecular Diagnostics Lead, CIO, CTO, Health IT Director, Procurement Manager, Strategic Sourcing Manager, Alliance Manager, Business Development Director | Best-fit functional targets for B2B outreach around this event theme |
| Geography | Japan first; Tokyo; Greater Tokyo Area; APAC; selected United States and Europe oncology hubs | Matches likely attendance catchment and strategic conference reach |
| Employee size | 51-200; 201-500; 501-1000; 1001-5000; 5001-10000; 10000+ | Captures hospitals, university systems, biopharma, diagnostics, and medtech firms with formal buying structures |
| Keywords | oncology, cancer center, immunotherapy, precision medicine, molecular diagnostics, liquid biopsy, translational medicine, pathology, clinical trials, oncology AI, cancer genomics, survivorship | Improves precision when company industry labels are broad |
| Technologies, if relevant | AI/ML, genomics, sequencing, pathology software, imaging analytics, hospital information systems | Useful if the client sells enabling technology or software |
| Revenue range, if relevant | Mid-market to enterprise | Best fit for organizations able to fund research, clinical pilots, or enterprise solutions |
| Company type | Hospitals, university medical centers, research institutes, pharma, biotech, diagnostics, medtech, healthcare software firms, public health organizations | Builds a mixed buyer map around the event ecosystem |
| Funding / public company filters | Public companies for enterprise medtech/pharma; funded private biotech for innovation partnerships | Useful for prioritizing budget-ready accounts |
Suggested Apollo Search Logic: ("oncology" OR "cancer" OR "immunotherapy" OR "precision medicine" OR "molecular diagnostics" OR "liquid biopsy" OR "clinical trials" OR "translational medicine" OR "pathology" OR "genomics") AND (Director OR Head OR VP OR Chief OR Professor OR Principal Investigator OR Manager) within Hospital & Health Care, Pharmaceuticals, Biotechnology, Medical Devices, Research, and Higher Education accounts in Japan and APAC.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| User-provided event title, dates, city, country, venue note, and event description | Provided reference material | Working basis for event name, dates, city, country, subject matter, and likely attendee themes | Medium |
| Venue note: ANA Crowne Plaza Narita / various Tokyo locations | Provided reference material | Venue remains inconsistent in supplied details and should be re-verified against the official event page before commercial use | Low to Medium |
| No official organizer website, agenda, exhibitor list, speaker directory, or sponsor list supplied | Verification gap | Attendance figures, organizer identity, official website, and current-year confirmed participants could not be validated from supplied materials | High importance note |
| Sample buyer organizations listed in this report | Market-fit prospecting examples | Included as relevant target accounts for oncology conference outreach; not confirmed current-year attendees | Medium |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 4th International Conference on Innovations and Advances in Cancer Research and Treatment — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds